EQS-Adhoc: Ad hoc: MorphoSys AG announces preliminary Monjuvi revenues for 2022, publishes financial guidance for 2023 and reduces financial liability

To this: MorphoSys AG announces preliminary Monjuvi sales for 2022, publishes financial guidance for 2023 and reduces financial liability

Request FREE:
Stock market calendar 2023 as a wall poster!

EQS-Ad-hoc: MorphoSys AG / Key word(s): Forecast

To this: MorphoSys AG announces preliminary Monjuvi sales for 2022,

publishes financial guidance for 2023 and reduces financial


05.01.2023 / 11:33 CET/EST

Publication of inside information in accordance with Article 17 of the Ordinance

(EU) No. 596/2014, transmitted by EQS News – a service of EQS Group


The issuer / publisher is responsible for the content of the notification.

Publication of an inside information according to article 17 paragraph 1 of the

Regulation (EU) No. 596/2014

Planegg/Munich, January 05, 2023

To this: MorphoSys AG announces preliminary Monjuvi sales for 2022,

publishes financial guidance for 2023 and reduces financial


*Preliminary Monjuvi net product sales in the US in 2022

$89.4 million (EUR 84.9 million)

* Expected Monjuvi net product sales in the US in 2023 in the

In the range of US$ 80 to 95 million

* Preliminary unaudited financial liability from the collaboration

with Incyte of around EUR 220 million, a reduction of 360

EUR million

Die MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announces the preliminary

Net product sales of Monjuvi® in the US for the full year 2022 announced

and publishes the financial guidance for 2023. In this context

reduced MorphoSys its financial liability from the collaboration

with Incyte and records corresponding financial income.

Preliminary US net product sales of Monjuvi (tafasitamab-cxix).

amounts to US$ 25.3 million (EUR 24.0 million) for the fourth quarter of 2022

and for the full year 2022 to US$ 89.4 million (EUR 84.9 million). The results

for the fourth quarter and full year of 2022 will be on March 15, 2023

released. Expected for the full year 2023 MorphoSys for Monjuvi in

net product sales in the U.S. in the range of $80 million to $95 million


Due to the adjusted sales expectations for Monjuvi, the

Balance sheet item “Financial liabilities from collaborations” of 580

EUR million (as of September 30, 2022) to around EUR 220 million (as of December 31

2022; unchecked). The difference between the two is included in financial income

amounts recorded. The balance in “Financial liabilities from

Collaborations” reflects an accounting view of the expected

future profits on Monjuvi’s net product sales in the United States

for the treatment of relapsed or refractory diffuse large cell disease

B-Zell-Lymphoms (R/R DLBCL) wider, die MorphoSys his partner Incyte

owes. Reducing financial liabilities from

Collaborations has no impact on cash and cash equivalents.

Financial guidance for the full year 2023:

Fina- Comments on the 2023 Financial Outlook






Monjuvi 80 100% of Monjuvi’s US net sales

Net pro to are included in the profit and loss account of

ductum- 95 MorphoSys recorded, and the related

rate in million profit/loss will be half between MorphoSys and

the USA US$ Incyte divided.

Gross Mar- 75% 100% of Monjuvi’s cost of sales in the US

ge for to are included in the income statement from

US-Net- 80% MorphoSys recorded, and the related

to-Product Profit/Loss will be split in half MorphoSys and

revenue Incyte divided.



Expenses 290 2023 will be due to the expansion of

gene for up Pelabresib development program with a

Research 315 expected a slight increase compared to 2022.

and million

Development EUR



Expenses 140 45% to 50% of the mean expenses for

gen for to sales, administration and general

Distribution, 155 represent distribution costs of Monjuvi in ​​the

Administration million USA, of which 100% in the

and EUR Profit and Loss Account of MorphoSys

General. Incyte refunded MorphoSys die

nes half of those distribution costs.

Additional information on the 2023 financial outlook:

* The Tremfya royalties will continue to be recognized as revenue excluding

Cost of sales in MorphoSys’s income statement

expelled. These royalties will be MorphoSys but not liquid

Inject funds as 100% of royalties go to Royalty Pharma


* MorphoSys expects to receive royalties on Minjuvi® sales outside of the

to get United States.

* MorphoSys does not expect any significant cash-effective sales

Milestone payments in 2023.

* MorphoSys anticipates sales of both commercial and clinical

Material from tafasitamab outside the US to its partner Incyte. the

Proceeds from these deliveries are included in the profit and loss account

von MorphoSys in the category “Licenses, Milestones and Miscellaneous”

expelled. These sales result in a gross profit/one

Zero gross margin. Therefore there MorphoSys none for these transactions

forecast off.



Information and explanations of the issuer to this communication:

above MorphoSys:

at MorphoSys we have a clear mission: we want people with cancer

enable a better and longer life. As a global, commercial

focused biopharmaceutical company, we use cutting-edge science and

Technologies to discover, develop and

to make available to patients. MorphoSys has its headquarters in

Planegg, Germany and conducts its business in the USA from Boston,

Massachusetts. More information can be found at www.morphosys.de. consequences

us on LinkedIn and Twitter.

Monjuvi® is a registered trademark of MorphoSys AG.

Forward-Looking Statements

This release contains certain forward-looking statements about

die MorphoSys-Group of companies. They include known and unknown

Risks and uncertainties that may cause the actual

Results, financial position, liquidity, performance or achievements

von MorphoSys or the results of the industry significantly different from the historical

or future results, financial position, liquidity, performance

or the achievements described in such forward-looking statements

expressed or implied. Even if the results that

performance, financial condition and liquidity of MorphoSys as well as the

Development of the industry in which MorphoSys is active with the

forward-looking statements, these may not apply to the

infer results or developments in future periods. to

the factors that can lead to discrepancies include the fact that

the expectations of MorphoSys might be inaccurate, the inherent

Uncertainties related to developments in competition, clinical

Studies and product developments as well as official approval requirements,

the dependence on cooperation with third parties, the assessment of the

commercial potential of the development programs of MorphoSys and other

Risks included in the risk factors in the annual report of MorphoSys on

Form 20-F and others filed with the US Securities and Exchange Commission

documents are listed. In view of these uncertainties,

Readers are advised not to inappropriately refer to such

to rely on forward-looking statements. These forward-thinking

Statements speak only as of the date of this publication

Document. MorphoSys expressly disclaims any obligation contained in this

document contained forward-looking statements to update them

to changed expectations or to changed events, conditions or

to adjust the circumstances on which these statements are based or which

Probability affect the actual results from the

in the forward-looking statements, except to the extent that

is required by law or regulation.

For more information please contact:

dr Julia Neugebauer

Head of Investor Relations

Tel: +49 (0)89 / 899 27 179


01/05/2023 CET/CEST The EQS distribution services include statutory

reporting requirements, corporate news/financial news and press releases.

Media archive at https://eqs-news.com

Language: German

Company: MorphoSys AG

Semmelweisstr. 7

82152 Planegg


Phone: +49 (0)89 899 27-0

Fax: +49 (0)89 899 27-222

E-Mail: investors@morphosys.com

Internet: www.morphosys.com

ISIN: DE0006632003

WKN: 663200

indices: SDAXTecDAX

Stock exchanges: Regulated market in Frankfurt (Prime Standard);

Open market in Berlin, Dusseldorf, Hamburg, Hanover,

Munich, Stuttgart, Tradegate Exchange; Nasdaq

EQS News ID: 1527931

End of message EQS News Service

1527931 05.01.2023 CET/CEST


Source: dpa-AFX

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.